⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Official Title: A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Study ID: NCT00359086

Conditions

Lymphoma

Interventions

MGCD0103

Study Description

Brief Summary: In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Duke University Adult Bone Marrow Transplant Clinic, Durham, North Carolina, United States

MD Anderson Cancer Center, Houston, Texas, United States

Ottawa Hospital - General Campus, Ottawa, Ontario, Canada

Charles LeMoyne Hospital, Greenfield Park, Quebec, Canada

Sir Mortimer Davis-Jewish General Hospital, Montreal, Quebec, Canada

Contact Details

Name: Gregory Reid, MSc, MBA

Affiliation: MethylGene Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: